NCT07418125 Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA
| NCT ID | NCT07418125 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Oncology Ljubljana |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2024-02-07 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 130 participants in total. It began in 2024-02-07 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.
Eligibility Criteria
Inclusion Criteria: * Patients with inflammatory breast cancer, regardless of cancer subtype (stage IIID) * Patients with non-inflammatory breast cancer: triple-negative and HER2+ subtypes, from stage IIB to IIIA-C * Adequate health status for neoadjuvant systemic treatment Exclusion Criteria: * Inflammatory breast cancer stage IV * Luminal A, luminal B subtypes of non-inflammatory breast cancer * Stages I-IIA breast cancer * Inability to understand or communicate in Slovenian * Inability to follow protocol instructions * Inappropriate health status for chemotherapy treatment * Primary treatment with surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07418125 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07418125 currently recruiting?
Yes, NCT07418125 is actively recruiting participants. Contact the research team at kkorosec@onko-i.si for enrollment information.
Where is the NCT07418125 trial being conducted?
This trial is being conducted at Ljubljana, Slovenia.
Who is sponsoring the NCT07418125 clinical trial?
NCT07418125 is sponsored by Institute of Oncology Ljubljana. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.